Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05690971 · ClinicalTrials.gov registry record · NA
Psychosocial Mobile App for Chronic Graft-Versus-Host Disease
A NA study of Chronic Graft Versus Host Disease and Allogeneic Stem Cell Transplant, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05690971: Active NA study of Chronic Graft Versus Host Disease and Allogeneic Stem Cell Transplant, sponsored by Massachusetts General Hospital.
NCT05690971 is a NA study of Chronic Graft Versus Host Disease and Allogeneic Stem Cell Transplant that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 120 participants, roughly in line with the 112-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05690971, a NA study of Chronic Graft Versus Host Disease and Allogeneic Stem Cell Transplant, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to see whether a psychosocial mobile app called Horizons is effective at improving quality of life, symptom burden, psychological distress, and coping in patients living with chronic graft-versus host disease (GVHD)
Primary Outcome
Compare patient QOL (FACT-BMT) between usual care and Horizon at 8 weeks using ANCOVA. FACT-BMT score range 0-164, with higher scores indicating better quality of life.
Conditions Studied
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL App
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-01-23 |
| Est. Completion | 2026-06-01 |
| Phase | NA |
What the registry record for NCT05690971 still lists
NCT05690971 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 112-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target.
The record links to 2 conditions, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT05690971 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05690971 about?
NCT05690971 is a clinical study titled "Psychosocial Mobile App for Chronic Graft-Versus-Host Disease". The purpose of this research study is to see whether a psychosocial mobile app called Horizons is effective at improving quality of life, symptom burden, psychological distress, and coping in patients living with chronic graft-versus host disease (GVHD)
What is the current status of trial NCT05690971?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-01-23. Estimated completion is 2026-06-01.
What conditions does trial NCT05690971 study?
This clinical trial studies the following conditions: Chronic Graft Versus Host Disease, Allogeneic Stem Cell Transplant.
What interventions are being tested in trial NCT05690971?
The interventions under investigation include: Usual Care (BEHAVIORAL), App (BEHAVIORAL).
Who is sponsoring clinical trial NCT05690971?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05690971 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft Versus Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05690971's enrollment target sits among peer trials
120 8th of 30 higher than 22 of 30 other Chronic Graft Versus Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Graft Versus Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
RECRUITING · NA
-
Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease
ACTIVE NOT RECRUITING · NA
-
Digital Health Intervention to Promote Quality of Life in Adults With Chronic Graft Versus Host Disease
ACTIVE NOT RECRUITING · NA
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI